Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies
Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies
复制标题
DOI：
10.1016/j.jaad.2006.12.024
复制
发表时间：
2007-05-01
影响因子：
13.8
通讯作者：
Helm, Klaus F.
中科院分区：
文献类型：
--
作者：
Fulchiero, Gregory J., Jr.;Salvaggio, Heather;Helm, Klaus F.
我们报告两例晚期复发的发疹性局部转移性黑色素瘤发生在明确的手术治疗后6年和9年。每例病例（IB期和IA期）分别发生在开始皮下抗肿瘤坏死因子药物依那西普和阿达木单抗治疗后。我们讨论了协会的免疫抑制和黑色素瘤。这些病例说明了肿瘤坏死因子-α抑制和潜伏性黑色素瘤再活化之间先前未被认识的潜在因果关系。
We report two cases of late recurrence of eruptive locoregional metastatic melonoma occuring 6 and 9 years after definitive surgical treatment. Each case (stage IB and IA) occurred after initiation of the subcutaneous anti-tumor necrosis factor medication etanercept and adalimumab, respectively. We discuss the association of immune suppression and melonoma. These cases illustrate a previously unrecognized and potentially causal relationship between tumor necrosis factor-alpha inhibition and reactivation of latent melanoma.